Carlos R.
- Country
- Spain
- Department
- Hematología
Research Overview
- A Phase 1/2 Study of Enzomenib (DSP 5336) in Adults with Relapsed or Refractory Acute Leukemia, Including MLL-Rearranged or NPM1-Mutated Subtypes
- Efficacy and Safety of Oral Decitabine and Ivosidenib in Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Data & Insights
Has run more than one trial at 4 of 46 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in researching therapeutic approaches for acute myeloid leukemia (AML), with particular emphasis on cases involving IDH1 mutations. Their work focuses on developing treatment strategies for patients who cannot undergo intensive chemotherapy treatments.
- Blood Cancer Treatment
- Mutation-Specific Therapy
- Alternative Treatment Approaches
The research extends to combination therapy approaches using targeted agents in hematologic malignancies.
Molecular Therapeutics
This investigator has developed expertise in targeted molecular therapies, specifically focusing on treatments that address specific genetic mutations in blood cancers. Their work involves investigating novel therapeutic combinations for improved patient outcomes.
- Precision Medicine
- Genetic Mutation Analysis
- Combination Treatment Strategies
Their research emphasizes the development of personalized treatment approaches based on genetic profiles.
Treatment Safety
The investigator specializes in evaluating the safety and tolerability profiles of novel therapeutic combinations in vulnerable patient populations. Their work focuses on developing treatment options for patients who require alternative approaches to standard intensive therapies.
- Drug Safety Assessment
- Patient Tolerance Studies
- Risk Management
Their research prioritizes understanding treatment effects in specific patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.